You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Details for New Drug Application (NDA): 020287

✉ Email this page to a colleague

NDA 020287 describes FRAGMIN, which is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier. Additional details are available on the FRAGMIN profile page.

The generic ingredient in FRAGMIN is dalteparin sodium. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dalteparin sodium profile page.

Summary for 020287

Tradename:	FRAGMIN
Applicant:	Pfizer
Ingredient:	dalteparin sodium
Patents:	0

Pharmacology for NDA: 020287

Medical Subject Heading (MeSH) Categories for 020287

Anticoagulants
Fibrinolytic Agents

Suppliers and Packaging for NDA: 020287

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
FRAGMIN	dalteparin sodium	INJECTABLE;INJECTION	020287	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0195	0069-0195-02	10 SYRINGE in 1 CARTON (0069-0195-02) / .2 mL in 1 SYRINGE (0069-0195-01)
FRAGMIN	dalteparin sodium	INJECTABLE;SUBCUTANEOUS	020287	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0195	0069-0195-02	10 SYRINGE in 1 CARTON (0069-0195-02) / .2 mL in 1 SYRINGE (0069-0195-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;SUBCUTANEOUS			Strength	2,500IU/0.2ML (12,500IU/ML)
Approval Date:	Dec 22, 1994	TE:		RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;SUBCUTANEOUS			Strength	10,000IU/0.4ML (25,000IU/ML)
Approval Date:	May 1, 2007	TE:		RLD:	No

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;SUBCUTANEOUS			Strength	5,000IU/0.2ML (25,000IU/ML)
Approval Date:	Mar 18, 1996	TE:		RLD:	Yes

Expired US Patents for NDA 020287

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	FRAGMIN	dalteparin sodium	INJECTABLE;SUBCUTANEOUS	020287-001	Dec 22, 1994	⤷ Get Started Free	⤷ Get Started Free
Pfizer	FRAGMIN	dalteparin sodium	INJECTABLE;SUBCUTANEOUS	020287-004	Jan 30, 1998	⤷ Get Started Free	⤷ Get Started Free
Pfizer	FRAGMIN	dalteparin sodium	INJECTABLE;SUBCUTANEOUS	020287-003	Mar 18, 1996	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.